Javascript must be enabled to continue!
Predictors of statin adherence in primary care using real-world data
View through CrossRef
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary prevention of CVD among patients in the first two years after the date of first prescription using real-world data.
Methods
The Electronic Practice Based Research Network Linked Dataset was used in this study. Statin adherence was calculated using a modified proportion of days covered (PDC) formula. Individuals with PDC ≥ 80% during the two years of observation period were considered as adherent. All analyses were performed with R software. Descriptive and multivariate logistic regression analyses were performed. Sensitivity analysis was performed using the Akaike Information Criterion model selection method.
Results
Overall, 3,432 patients accounting for 57,227 visits met the selection criteria. The mean PDC was 91.6% (±22.2%), and 72.0% of the patients were adherent to statins (PDC ≥ 80%) in the first two years after the date of first prescription. After adjusting for all other variables, statin adherence was positively associated with age (AOR 1.7, 95% CI 1.4 – 2.0), SEIFA index (AOR 1.8, 95% CI 1.2 – 2.6), polypharmacy (AOR 1.8, 95% CI 1.3 – 2.5) and comorbidities (AOR 1.4, 95% CI 1.1 – 1.7), and negatively associated with the number of statin types (AOR 0.6, 95% CI 0.5 – 0.9) and smoking status (AOR 0.7, 95% CI 0.6 – 0.9). The sensitivity analysis showed similar results as the regression model.
Conclusions
Statin adherence is influenced by an aging, multimorbid population, who are exposed to polypharmacy, multiple statin options and socioeconomic diversity.
Key points
Adherence in the first two years after the first date of statin prescription was measured as proportion of days covered (PDC)
The mean PDC was 91.6% (±22.2%)
72.0% of the patients were adherent to statins, with PDC ≥ 80%
Statin adherence was positively associated with age, area-based social advantage and disadvantage index, polypharmacy and comorbidities
Statin adherence was negatively associated with the number of statin types prescribed to the patients and the smoking status of patients
Plain Language Summary
The objective of this study was to identify predictors of statin adherence among patients in the first two years after the date of first prescription using real-world data. The dataset used was the Electronic Practice Based Research Network Linked Dataset. Statin adherence was calculated using proportion of days covered (PDC). A PDC ≥ 80% during the two years of observation period were considered as adherent. Overall, 3,432 patients were eligible for this study, and 72.0% of them were adherent to statins in the first two years after the date of first prescription. Statin adherence was positively associated with age, area-based social advantage and disadvantage index, number of medicines taken by the patient and number of chronic conditions that the patient suffered. Moreover, statin adherence was negatively associated with the number of statin types prescribed to the patients and smoking status of patients.
Title: Predictors of statin adherence in primary care using real-world data
Description:
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary prevention of CVD among patients in the first two years after the date of first prescription using real-world data.
Methods
The Electronic Practice Based Research Network Linked Dataset was used in this study.
Statin adherence was calculated using a modified proportion of days covered (PDC) formula.
Individuals with PDC ≥ 80% during the two years of observation period were considered as adherent.
All analyses were performed with R software.
Descriptive and multivariate logistic regression analyses were performed.
Sensitivity analysis was performed using the Akaike Information Criterion model selection method.
Results
Overall, 3,432 patients accounting for 57,227 visits met the selection criteria.
The mean PDC was 91.
6% (±22.
2%), and 72.
0% of the patients were adherent to statins (PDC ≥ 80%) in the first two years after the date of first prescription.
After adjusting for all other variables, statin adherence was positively associated with age (AOR 1.
7, 95% CI 1.
4 – 2.
0), SEIFA index (AOR 1.
8, 95% CI 1.
2 – 2.
6), polypharmacy (AOR 1.
8, 95% CI 1.
3 – 2.
5) and comorbidities (AOR 1.
4, 95% CI 1.
1 – 1.
7), and negatively associated with the number of statin types (AOR 0.
6, 95% CI 0.
5 – 0.
9) and smoking status (AOR 0.
7, 95% CI 0.
6 – 0.
9).
The sensitivity analysis showed similar results as the regression model.
Conclusions
Statin adherence is influenced by an aging, multimorbid population, who are exposed to polypharmacy, multiple statin options and socioeconomic diversity.
Key points
Adherence in the first two years after the first date of statin prescription was measured as proportion of days covered (PDC)
The mean PDC was 91.
6% (±22.
2%)
72.
0% of the patients were adherent to statins, with PDC ≥ 80%
Statin adherence was positively associated with age, area-based social advantage and disadvantage index, polypharmacy and comorbidities
Statin adherence was negatively associated with the number of statin types prescribed to the patients and the smoking status of patients
Plain Language Summary
The objective of this study was to identify predictors of statin adherence among patients in the first two years after the date of first prescription using real-world data.
The dataset used was the Electronic Practice Based Research Network Linked Dataset.
Statin adherence was calculated using proportion of days covered (PDC).
A PDC ≥ 80% during the two years of observation period were considered as adherent.
Overall, 3,432 patients were eligible for this study, and 72.
0% of them were adherent to statins in the first two years after the date of first prescription.
Statin adherence was positively associated with age, area-based social advantage and disadvantage index, number of medicines taken by the patient and number of chronic conditions that the patient suffered.
Moreover, statin adherence was negatively associated with the number of statin types prescribed to the patients and smoking status of patients.
Related Results
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract
Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
Background and Aims: Here, we compared the effects of combination therapy of low- or moderate-statin with ezetimibe and high-intensity statin monotherapy in patients with type 2 di...
Abstract 112: Statin Utilization in the Outpatient Clinic of a University Based Residency Training Program
Abstract 112: Statin Utilization in the Outpatient Clinic of a University Based Residency Training Program
Background:
Current guidelines released in 2013 recommend statins for five specific patient groups including persons with clinical atherosclerotic cardiovascular diseas...
Investigation of the Statin Paradox in Different Populations of VICs
Investigation of the Statin Paradox in Different Populations of VICs
Abstract
While numerous clinical studies have examined the effect of HMG-CoA reductase inhibitors (statin drugs) on calcific aortic valve disease (CAVD), their co...
Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009–2017
Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009–2017
Abstract
Background
Previous studies have shown that use of statins for secondary prevention of cardiovascular disease (CVD) is ...
Electronic health record (EHR)-detectable statin intolerance phenotypes: Prevalence and validation in real-world general practice
Electronic health record (EHR)-detectable statin intolerance phenotypes: Prevalence and validation in real-world general practice
ABSTRACT
Aims
This study focused on patients who were prescribed statins as primary prevention of cardiovascular diseases. This...
Statin use and the risk of Acute Myeloid Leukemia: A retrospective propensity-matched cohort study
Statin use and the risk of Acute Myeloid Leukemia: A retrospective propensity-matched cohort study
Abstract
Background: Statins, among the most widely prescribed medications worldwide, inhibit the mevalonate pathway and...
Does Preoperative Statin Exposure Reduce Prosthetic Joint Infections and Revisions Following Total Joint Arthroplasty?
Does Preoperative Statin Exposure Reduce Prosthetic Joint Infections and Revisions Following Total Joint Arthroplasty?
Introduction: The pleiotropic effects of statins extend beyond managing cardiovascular health and are suggested to modulate Staphylococcus aureus biofilm formation with prosthetic ...

